Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Foghorn Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Foghorn Therapeutics Inc.’s stock price such as:

• Foghorn Therapeutics Inc.’s current stock price and volume
• Why Foghorn Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for FHTX from analysts
• FHTX’s stock price momentum as measured by its relative strength

About Foghorn Therapeutics Inc. (FHTX)

Before we jump into Foghorn Therapeutics Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Foghorn Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Foghorn Therapeutics Inc..

Foghorn Therapeutics Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Foghorn Therapeutics Inc.’s stock price was $4.750.

Foghorn Therapeutics Inc. is down 1.25% from its previous closing price of $4.810.

During the last market session, Foghorn Therapeutics Inc.’s stock traded between $4.645 and $4.870. Currently, there are approximately 63.03 million shares outstanding for Foghorn Therapeutics Inc..

Foghorn Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Foghorn Therapeutics Inc. Stock Price History

Foghorn Therapeutics Inc.’s (FHTX) price is currently up 7.71% so far this month.

During the month of November, Foghorn Therapeutics Inc.’s stock price has reached a high of $5.690 and a low of $3.270.

Over the last year, Foghorn Therapeutics Inc. has hit prices as high as $8.445 and as low as $2.945. Year to date, Foghorn Therapeutics Inc.’s stock is up 0.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Foghorn Therapeutics Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of November 28, 2025,, no analysts have changed their rating of Foghorn Therapeutics Inc.’s stock over the last month.

Additionally, you'll want to evaluate Foghorn Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Foghorn Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Foghorn Therapeutics Inc. (FHTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Foghorn Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Foghorn Therapeutics Inc. has a weighted four-quarter relative price strength of -12.00%, which translates to a Momentum Score of 20 and is considered to be Very Weak.

Want to learn more about how Foghorn Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Foghorn Therapeutics Inc. Stock Price: Bottom Line

As of November 28, 2025, Foghorn Therapeutics Inc.’s stock price is $4.750, which is down 1.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Foghorn Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.